
Craig Davis is the President and CEO of NovaScan, a Chicago-based clinical-stage oncology company building a low-cost, point-of-care platform that uses bioimpedance and machine learning to detect and stratify cancer in real time. A medtech executive and investor with more than two decades of experience, he has raised over $20 million for NovaScan, secured a CPRIT grant, and helped steer clinical trials in skin, lung, breast, GI and pancreatic cancers. Earlier in his career he helped shape companies including New Aera (acquired by Inogen), Merge Healthcare (IPO; later acquired by IBM), and OrthoScan, and was a partner at healthcare investment bank Healthios.
Alexander Casdin is the Chief Executive Officer of Epirium Bio, a San Diego biotechnology company developing small-molecule therapies to improve muscle function. A healthcare executive and institutional investor with more than 25 years in the industry, he stepped up from CFO and COO to CEO on January 1, 2025, the same month Epirium's lead drug MF-300 - a first-in-class oral 15-PGDH inhibitor for sarcopenia - cleared the FDA to begin human trials. Before Epirium he founded and ran Reneo Capital Management, was CFO of Sophiris Bio, and ran VP of Finance at Amylin Pharmaceuticals, and he sits on the board of Erasca as audit committee chair.
Dr. Shubhra Jain, MD, MBA is Chief Business Officer at Hippocratic AI, the $3.5B generative AI healthcare company building the world's safest patient-facing AI agents. A rare triple threat - trained primary care physician, Stanford engineer (MS Biodesign), and Wharton MBA - she brings a decade of healthcare investing and product leadership to Hippocratic AI's commercial strategy. Before joining HAI, she led healthcare investing at Tarsadia Investments and Cota Capital, and held product leadership roles at Natera and Pieces Technologies. A first-generation immigrant from a small Indian town, she is a passionate advocate for health equity, underrepresented founders, and making healthcare abundant for all.